Vol.44, No.4, 2020, pp.591-595, doi:10.32604/biocell.2020.011642
OPEN ACCESS
ARTICLE
Chaperone-mediated autophagy targeting chimeras (CMATAC) for the degradation of ERα in breast cancer
  • JUN ZHANG, YEHONG HUANG, WENZHUO LIU, LULU LI, LIMING CHEN*
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, Department of Biochemistry, School of Life Sciences, Nanjing Normal University, Nanjing, 210023, China
* Address correspondence to: Liming Chen,
Received 21 May 2020; Accepted 19 August 2020; Issue published 24 December 2020
Abstract
Estrogen receptor alpha (ERα/ESR1) is overexpressed in over half of all breast cancers and is considered a valuable therapeutic target in ERα positive breast cancer. Here, we designed a membrane-permeant Chaperonemediated Autophagy Targeting Chimeras (CMATAC) peptide to knockdown endogenous ERα protein through chaperone-mediated autophagy. The peptide contains a cell membrane-penetrating peptide (TAT) that allows the peptide to by-pass the plasma membrane, an αI peptide as a protein-binding peptide (PBD) that binds specifically to ERα, and CMA-targeting peptide (CTM) that targeting chaperone-mediated autophagy. We validated that ERα targeting peptide was able to target and degrade ERα to reduce the viability of ERα positive breast cancer cells. Taken together, our studies provided a new method to reduce the level of intracellular ERα protein via CMATAC, and thus may provide a new strategy for the treatment of ERα positive breast cancer.
Keywords
Chaperone-mediated Autophagy Targeting Chimeras (CMATAC), Breast cancer, Peptide, ERα
Cite This Article
ZHANG, J., HUANG, Y., LIU, W., LI, L., CHEN, L. (2020). Chaperone-mediated autophagy targeting chimeras (CMATAC) for the degradation of ERα in breast cancer. BIOCELL, 44(4), 591–595.
Citations
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.